Benzinga | Jan 11, 2021 07:16AM EST

Format Therapeutics Provides 2021 Priorities

Strong pipeline progress in 2020 positions company well for 2021

Established proof of concept in SCD for FT-4202

Potential transformative treatment profile for IDH1 inhibitor olutasidenib in R/R/ AML

Enrolling Phase 1 FT-7051 trial for prostate cancer - including patient with AR-v7 splice variants

Completed successful IPO and follow-on equity offering